PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
19-Feb-2020 Immutep reports positive TACTI-002 data Immutep
19-Feb-2020 Orgenesis announces collaboration with the John Hopkins University for the development and processing of cell and gene based clinical therapeutics Orgenesis
19-Feb-2020 European Commission Grants Marketing Authorisation for VYNDAQEL®  (tafamidis), the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pfizer
19-Feb-2020 SEARCHING FOR BIOMARKERS AND THERPEUTIC AGENTS AGAINST BREAST CANCER Karl Landsteiner University
19-Feb-2020 COUNTDOWN TO THE HSJ PARTNERSHIP AWARDS 2020 HSJ Partnership Awards
18-Feb-2020 IDDI INTENSIFIES GLOBAL DEBATE ON THE FUTURE OF RANDOMIZED TRIALS IN CLINICAL RESEARCH International Drug Development Institute (IDDI),
18-Feb-2020 Director resignation - H.J. Mark Tompkins NMC HEALTH PLC
18-Feb-2020 Director resignation - Mr Abdulrahman Basaddiq NMC HEALTH PLC
18-Feb-2020 Director resignation - Hani Buttikhi NMC HEALTH PLC
18-Feb-2020 New company takes aim at treatments for multiple sclerosis Pheno Therapeutics
18-Feb-2020 DNX Biopharmaceuticals Announces Collaboration With Lung Cancer Initiative at Johnson & Johnson DNX Biopharmaceuticals, Inc
18-Feb-2020 Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine Sanofi
18-Feb-2020 Signant Health invests for growth with the opening of its new Philadelphia-area office Signant Health
17-Feb-2020 Director resignation NMC Health plc
17-Feb-2020 Castor provides free access to data capture platform to support non-profit COVID19 research projects Castor
17-Feb-2020 ReNeuron Group plc - Positive Phase 2a stroke clinical data published ReNeuron Group plc
17-Feb-2020 Vifor Pharma acquires Priority Review Voucher Vifor Pharma Group
17-Feb-2020 Analysis of RNA sequences and modifications by mass spectrometry published in Nature Communications STORM Therapeutics Ltd
17-Feb-2020 Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease Takeda Pharmaceutical Company Limited
17-Feb-2020 OMass Therapeutics Announces £27.5 Million Extended Series A Financing OMass Therapeutics